BeOne Medicines AG (FRA:49BA)

Market Cap	31.70B +51.7%
Revenue (ttm)	4.24B +50.4%
Net Income	58.43M
EPS	0.50
Shares Out	n/a
PE Ratio	542.63
Forward PE	64.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4
Average Volume	1
Open	290.00
Previous Close	286.00
Day's Range	290.00 - 290.00
52-Week Range	180.00 - 322.00
Beta	n/a
RSI	55.28
Earnings Date	Apr 15, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 49BA

Financial Performance

In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD